Robin Schmitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robin Schmitz has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Allan Kirk
Department of Surgery, Duke University School of Medicine, Durham, NC
4 shared publications Dan G. Blazer
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
4 shared publications- Mingqing Song
Duke Ex-Vivo Organ Lab, Duke University, Department of Surgery
4 shared publications - Alton Brad Farris
Department of Pathology, Emory University, Atlanta, Georgia, USA
3 shared publications - Brian I. Shaw
Department of Surgery, Duke University, Durham, NC
3 shared publications Dimitrios Moris
Department of Surgery Duke University School of Medicine Durham North Carolina 27710 USA
3 shared publications
Latest Publications
- 29 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (12) , 2116-2130
Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates
Key Points: Belatacept-based maintenance immunosuppression prevents antibody-mediated rejection and enables long-term kidney allograft survival in sensitized nonhuman primate recipients. Post-transplant belatacept prevents the rebound of follicular helper T cells, class-switched B cells, and antibody-secreting cells. Additional belatacept with tacrolimus increases the risk of viral reactivation and post-transplant lymphoproliferative disease. Preexisting donor-specific antibodies (DSA) to MHC antigens increase the risk of antibody-mediated rejection (AMR) in sensitized transplant recipients and reduces graft survival. Pretransplant desensitization with costimulation blockade and proteasome inhibition has facilitated transplantation in our preclinical nonhuman primate (NHP) model. However, long-term graft survival is limited by rebound of DSA after transplantation. In this study, we performed kidney transplants between highly sensitized, maximally MHC-mismatched NHPs (n=14). At kidney transplantation, primates received T cell depletion with rhesus-specific anti-thymocyte globulin (rhATG; n=10) or monoclonal anti-CD4 and anti-CD8 antibodies (n=4). Maintenance immunosuppression consisted of belatacept and tacrolimus (n=5) or belatacept and rapamycin (n=9) with steroids. Rebound of DSA post–kidney transplantation was significantly reduced compared with maintenance immunosuppression with tacrolimus, mycophenolate, and steroids. Protocol lymph node biopsy specimens showed a decrease in germinal center activity, with low frequencies of T follicular helper cells and class-switched B cells after kidney transplantation. Combined belatacept and rapamycin was superior in controlling viral reactivation, enabling weaning of ganciclovir prophylaxis. Tacrolimus was associated with increased morbidity that included cytomegalovirus and parvovirus viremia and post-transplant lymphoproliferative disorder. All primates in the tacrolimus/belatacept group failed discontinuation of antiviral therapy. Overall, belatacept-based immunosuppression increased AMR-free graft survival by controlling post-transplant humoral responses in highly sensitized NHP recipients and should be further investigated in a human clinical trial.
- 29 December 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (12) , 2116-2130
Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates
Key Points: Belatacept-based maintenance immunosuppression prevents antibody-mediated rejection and enables long-term kidney allograft survival in sensitized nonhuman primate recipients. Post-transplant belatacept prevents the rebound of follicular helper T cells, class-switched B cells, and antibody-secreting cells. Additional belatacept with tacrolimus increases the risk of viral reactivation and post-transplant lymphoproliferative disease. Preexisting donor-specific antibodies (DSA) to MHC antigens increase the risk of antibody-mediated rejection (AMR) in sensitized transplant recipients and reduces graft survival. Pretransplant desensitization with costimulation blockade and proteasome inhibition has facilitated transplantation in our preclinical nonhuman primate (NHP) model. However, long-term graft survival is limited by rebound of DSA after transplantation. In this study, we performed kidney transplants between highly sensitized, maximally MHC-mismatched NHPs (n=14). At kidney transplantation, primates received T cell depletion with rhesus-specific anti-thymocyte globulin (rhATG; n=10) or monoclonal anti-CD4 and anti-CD8 antibodies (n=4). Maintenance immunosuppression consisted of belatacept and tacrolimus (n=5) or belatacept and rapamycin (n=9) with steroids. Rebound of DSA post–kidney transplantation was significantly reduced compared with maintenance immunosuppression with tacrolimus, mycophenolate, and steroids. Protocol lymph node biopsy specimens showed a decrease in germinal center activity, with low frequencies of T follicular helper cells and class-switched B cells after kidney transplantation. Combined belatacept and rapamycin was superior in controlling viral reactivation, enabling weaning of ganciclovir prophylaxis. Tacrolimus was associated with increased morbidity that included cytomegalovirus and parvovirus viremia and post-transplant lymphoproliferative disorder. All primates in the tacrolimus/belatacept group failed discontinuation of antiviral therapy. Overall, belatacept-based immunosuppression increased AMR-free graft survival by controlling post-transplant humoral responses in highly sensitized NHP recipients and should be further investigated in a human clinical trial.
- 15 September 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (12) , 7248-7249
Overcoming Treatment Disparities for Early-Stage Hepatocellular Carcinoma in the Veteran Population: Is the MISSION Act the Solution?
- 15 September 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (12) , 7248-7249
Overcoming Treatment Disparities for Early-Stage Hepatocellular Carcinoma in the Veteran Population: Is the MISSION Act the Solution?
- 1 November 2021
- Published by Wiley in Xenotransplantation
- Vol. 28 (6) , e12713
Anti‐thymoglobulin induction improves neonatal porcine xenoislet engraftment and survival
Porcine islet xenotransplantation is a viable strategy to treat diabetes. Its translation has been limited by the pre‐clinical development of a clinically available immunosuppressive regimen. We tested two clinically relevant induction agents in a non‐human primate (NHP) islet xenotransplantation model to compare depletional versus nondepletional induction immunosuppression. Neonatal porcine islets were isolated from GKO or hCD46/GKO transgenic piglets and transplanted via portal vein infusion in diabetic rhesus macaques. Induction therapy consisted of either basiliximab (n = 6) or rhesus‐specific anti‐thymocyte globulin (rhATG, n = 6), combined with a maintenance regimen using B7 costimulation blockade, tacrolimus with a delayed transition to sirolimus, and mycophenolate mofetil. Xenografts were monitored by blood glucose levels and porcine C‐peptide measurements. Of the six receiving basiliximab induction, engraftment was achieved in 4 with median graft survival of 14 days. All six receiving rhATG induction engrafted with significantly longer xenograft survival at 40.5 days (P = 0.03). These data suggest that depletional induction provides superior xenograft survival to nondepletional induction, in the setting of a costimulation blockade‐based maintenance regimen.
- 1 November 2021
- Published by Wiley in Xenotransplantation
- Vol. 28 (6) , e12713
Anti‐thymoglobulin induction improves neonatal porcine xenoislet engraftment and survival
Porcine islet xenotransplantation is a viable strategy to treat diabetes. Its translation has been limited by the pre‐clinical development of a clinically available immunosuppressive regimen. We tested two clinically relevant induction agents in a non‐human primate (NHP) islet xenotransplantation model to compare depletional versus nondepletional induction immunosuppression. Neonatal porcine islets were isolated from GKO or hCD46/GKO transgenic piglets and transplanted via portal vein infusion in diabetic rhesus macaques. Induction therapy consisted of either basiliximab (n = 6) or rhesus‐specific anti‐thymocyte globulin (rhATG, n = 6), combined with a maintenance regimen using B7 costimulation blockade, tacrolimus with a delayed transition to sirolimus, and mycophenolate mofetil. Xenografts were monitored by blood glucose levels and porcine C‐peptide measurements. Of the six receiving basiliximab induction, engraftment was achieved in 4 with median graft survival of 14 days. All six receiving rhATG induction engrafted with significantly longer xenograft survival at 40.5 days (P = 0.03). These data suggest that depletional induction provides superior xenograft survival to nondepletional induction, in the setting of a costimulation blockade‐based maintenance regimen.
- Open Access
- 24 September 2021
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 26 (09) , 096008-13
Optical coherence tomography of small intestine allograft biopsies using a handheld surgical probe
Intestinal transplant (IT) is a life-saving therapy for patients who are unable to absorb adequate nutrients, due to either disease or injury. The small intestine is commonly deemed one of the most challenging organs to be transplanted because of its enhanced immune response.1 Even with many advancements in the field, IT grafts are hypersensitive to reperfusion injury and more vulnerable to rejection, with the 10-year graft and patient survival rates still under 50% and 75%, respectively.2 Unlike other solid organ transplant models, there are no universally accepted biochemical markers with which to diagnose, monitor, or even predict IT graft failure.3 The current gold standard for post-IT evaluation involves constant and coordinated clinical, laboratory, and histopathologic testing. However, there is considerable variability over the approach and frequency of routine biopsy of acute cellular rejection (ACR) across approved IT programs in the United States.4 Excessive excisional biopsy of IT grafts presents several challenges, including increased financial burdens and risk of hemorrhage, perforations, and infection.5
- 24 September 2021
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 26 (09) , 096008-13
Open AccessOptical coherence tomography of small intestine allograft biopsies using a handheld surgical probe
Intestinal transplant (IT) is a life-saving therapy for patients who are unable to absorb adequate nutrients, due to either disease or injury. The small intestine is commonly deemed one of the most challenging organs to be transplanted because of its enhanced immune response.1 Even with many advancements in the field, IT grafts are hypersensitive to reperfusion injury and more vulnerable to rejection, with the 10-year graft and patient survival rates still under 50% and 75%, respectively.2 Unlike other solid organ transplant models, there are no universally accepted biochemical markers with which to diagnose, monitor, or even predict IT graft failure.3 The current gold standard for post-IT evaluation involves constant and coordinated clinical, laboratory, and histopathologic testing. However, there is considerable variability over the approach and frequency of routine biopsy of acute cellular rejection (ACR) across approved IT programs in the United States.4 Excessive excisional biopsy of IT grafts presents several challenges, including increased financial burdens and risk of hemorrhage, perforations, and infection.5
- Open Access
- 15 September 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates
Sensitized kidney transplant recipients experience high rates of antibody-mediated rejection due to the presence of donor-specific antibodies and immunologic memory. Here we show that transient peri-transplant treatment with the central complement component C3 inhibitor Cp40 significantly prolongs median allograft survival in a sensitized nonhuman primate model. Despite donor-specific antibody levels remaining high, fifty percent of Cp40-treated primates maintain normal kidney function beyond the last day of treatment. Interestingly, presence of antibodies of the IgM class associates with reduced median graft survival (8 vs. 40 days;p = 0.02). Cp40 does not alter lymphocyte depletion by rhesus-specific anti-thymocyte globulin, but inhibits lymphocyte activation and proliferation, resulting in reduced antibody-mediated injury and complement deposition. In summary, Cp40 prevents acute antibody-mediated rejection and prolongs graft survival in primates, and inhibits T and B cell activation and proliferation, suggesting an immunomodulatory effect beyond its direct impact on antibody-mediated injury.
- 15 September 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Open AccessC3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates
Sensitized kidney transplant recipients experience high rates of antibody-mediated rejection due to the presence of donor-specific antibodies and immunologic memory. Here we show that transient peri-transplant treatment with the central complement component C3 inhibitor Cp40 significantly prolongs median allograft survival in a sensitized nonhuman primate model. Despite donor-specific antibody levels remaining high, fifty percent of Cp40-treated primates maintain normal kidney function beyond the last day of treatment. Interestingly, presence of antibodies of the IgM class associates with reduced median graft survival (8 vs. 40 days;p = 0.02). Cp40 does not alter lymphocyte depletion by rhesus-specific anti-thymocyte globulin, but inhibits lymphocyte activation and proliferation, resulting in reduced antibody-mediated injury and complement deposition. In summary, Cp40 prevents acute antibody-mediated rejection and prolongs graft survival in primates, and inhibits T and B cell activation and proliferation, suggesting an immunomodulatory effect beyond its direct impact on antibody-mediated injury.
- 31 May 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (8) , e14369
A comparative study of human‐and rhesus‐specific antithymocyte globulins in Rhesus macaques
Rabbit antithymocyte globulin (RATG) preparations are widely used in transplantation. They are developed in vivo against thymocytes and contain polyclonal antibodies specific for myriad cellular targets. The rhesus monkey is commonly used as a preclinical transplant model, but the fidelity of commercially available human‐specific RATGs to anticipate the effects of RATGs in rhesus has not been established. We therefore developed two rhesus‐specific ATGs (rhATG) and compared them to human‐specific RATG (huATG, Thymoglobulin®) in rhesus monkeys, assessing the magnitude and phenotype of depletion peripherally and in lymph nodes. Four primates were assigned to each group and received 20 mg/kg of drug. Depletion, repopulation, and changes in lymphocyte subsets were evaluated in peripheral blood and lymph nodes by flow cytometry over four months. We observed similar qualitative changes in lymphocyte subsets, but a generally more profound depletion with huATG compared to either rhATG. Peripheral homeostatic proliferation rather than thymic output was the major mechanism for repopulation with all RATGs. Repopulation was slower but qualitatively similar when examining RATGs in additional animals receiving concomitant chronic immunosuppression. Depletional induction is similar to human‐ and rhesus‐specific RATGs in rhesus macaques. Both rhesus‐ and human‐specific agents appear appropriate for preclinical modeling of clinical RATG use.
- 31 May 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (8) , e14369
A comparative study of human‐and rhesus‐specific antithymocyte globulins in Rhesus macaques
Rabbit antithymocyte globulin (RATG) preparations are widely used in transplantation. They are developed in vivo against thymocytes and contain polyclonal antibodies specific for myriad cellular targets. The rhesus monkey is commonly used as a preclinical transplant model, but the fidelity of commercially available human‐specific RATGs to anticipate the effects of RATGs in rhesus has not been established. We therefore developed two rhesus‐specific ATGs (rhATG) and compared them to human‐specific RATG (huATG, Thymoglobulin®) in rhesus monkeys, assessing the magnitude and phenotype of depletion peripherally and in lymph nodes. Four primates were assigned to each group and received 20 mg/kg of drug. Depletion, repopulation, and changes in lymphocyte subsets were evaluated in peripheral blood and lymph nodes by flow cytometry over four months. We observed similar qualitative changes in lymphocyte subsets, but a generally more profound depletion with huATG compared to either rhATG. Peripheral homeostatic proliferation rather than thymic output was the major mechanism for repopulation with all RATGs. Repopulation was slower but qualitatively similar when examining RATGs in additional animals receiving concomitant chronic immunosuppression. Depletional induction is similar to human‐ and rhesus‐specific RATGs in rhesus macaques. Both rhesus‐ and human‐specific agents appear appropriate for preclinical modeling of clinical RATG use.
- Open Access
- 20 May 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (9) , 3163-3174
Age-related effects on thymic output and homeostatic T cell expansion following depletional induction in renal transplant recipients
- 20 May 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (9) , 3163-3174
Open AccessAge-related effects on thymic output and homeostatic T cell expansion following depletional induction in renal transplant recipients
- 22 February 2021
- Published by Wiley in Xenotransplantation
- Vol. 28 (3) , e12680
Coagulation, inflammation, and CD46 transgene expression in neonatal porcine islet xenotransplantation
Background: Thrombosis is a known consequence of intraportal islet transplantation, particularly for xenogeneic islets. To define the origins of thrombosis after islet xenotransplantation and relate it to early inflammation, we examined porcine islets transplanted into non‐human primates using a dual‐transplant model to directly compare islet characteristics.Methods: α1,3‐Galactosyltransferase gene‐knockout (GTKO) islets with and without expression of the human complement regulatory transgene CD46 (hCD46) were studied. Biologically inert polyethylene microspheres were used to examine the generic pro‐thrombotic effects of particle embolization. Immunohistochemistry was performed 1 and 24 hours after transplantation.Results: Xeno‐islet transplantation activated both extrinsic and intrinsic coagulation pathways. The intrinsic pathway was also initiated by microsphere embolization, while extrinsic pathway tissue factor (TF) and platelet aggregation were more specific to engrafted islets. hCD46 expression significantly reduced TF, platelet, fibrin, and factor XIIIa accumulation in and around islets but did not alter intrinsic factor activation. Layers of TF+ cells emerged around islets within 24 hours, particularly co‐localized with vimentin, and identified as CD3+ and CD68+ cells inflammatory cells.Conclusions: These findings detail the origins of thrombosis following islet xenotransplantation, relate it to early immune activation, and suggest a role for transgenic hCD46 expression in its mitigation. Layers of TF‐positive inflammatory cells and fibroblasts around islets at 24 hours may have important roles in the progressive events of thrombosis, inflammatory cell recruitment, rejection, and the ultimate outcome of transplanted grafts. These suggest that the strategies targeting these elements could yield more progress toward successful xenogeneic islet engraftment and survival.
- 22 February 2021
- Published by Wiley in Xenotransplantation
- Vol. 28 (3) , e12680
Coagulation, inflammation, and CD46 transgene expression in neonatal porcine islet xenotransplantation
Background: Thrombosis is a known consequence of intraportal islet transplantation, particularly for xenogeneic islets. To define the origins of thrombosis after islet xenotransplantation and relate it to early inflammation, we examined porcine islets transplanted into non‐human primates using a dual‐transplant model to directly compare islet characteristics.Methods: α1,3‐Galactosyltransferase gene‐knockout (GTKO) islets with and without expression of the human complement regulatory transgene CD46 (hCD46) were studied. Biologically inert polyethylene microspheres were used to examine the generic pro‐thrombotic effects of particle embolization. Immunohistochemistry was performed 1 and 24 hours after transplantation.Results: Xeno‐islet transplantation activated both extrinsic and intrinsic coagulation pathways. The intrinsic pathway was also initiated by microsphere embolization, while extrinsic pathway tissue factor (TF) and platelet aggregation were more specific to engrafted islets. hCD46 expression significantly reduced TF, platelet, fibrin, and factor XIIIa accumulation in and around islets but did not alter intrinsic factor activation. Layers of TF+ cells emerged around islets within 24 hours, particularly co‐localized with vimentin, and identified as CD3+ and CD68+ cells inflammatory cells.Conclusions: These findings detail the origins of thrombosis following islet xenotransplantation, relate it to early immune activation, and suggest a role for transgenic hCD46 expression in its mitigation. Layers of TF‐positive inflammatory cells and fibroblasts around islets at 24 hours may have important roles in the progressive events of thrombosis, inflammatory cell recruitment, rejection, and the ultimate outcome of transplanted grafts. These suggest that the strategies targeting these elements could yield more progress toward successful xenogeneic islet engraftment and survival.